January 25, 2010

Hector J. Preciado  
Carla Saporta  
Robert Gnaizda  
The Greenlining Institute  
1918 University Avenue, Second Floor  
Berkeley, CA 94704

Re: In the Matter of Pfizer Inc. and Wyeth, Docket No. C-4267

Dear Mr. Preciado, Ms. Saporta, and Mr. Gnaizda:

Thank you for your comments on behalf of the Greenlining Institute regarding the proposed consent order accepted by the Federal Trade Commission for public comment in the above-captioned matter. Your letter indicates that you believe the Commission should hold public hearings on the proposed acquisition to determine whether the acquisition is in the public interest.

The Commission conducted its non-public review of the proposed transaction pursuant to its authority under Section 7 of the Clayton Act, 15 U.S.C. §18, and Section 5 of the Federal Trade Commission Act, 15 U.S.C. § 45. As such, the Commission’s review is limited to antitrust-related issues. Many of the concerns you cite are not antitrust-related issues. With respect to your comment that the merger will raise prices, unfairly protect patents, and interfere with the development of generic drugs, the Commission’s statement describes the lengthy and thorough investigation undertaken to determine any impact the proposed transaction may have on any human health market. Based on the evidence gathered in the investigation, the Commission concluded that the transaction does not raise anticompetitive concerns in any human health product market.

For these reasons, the Commission has determined that the public interest would best be served by issuing the Decision and Order in final form without modification. A copy of the final Decision and Order is enclosed for your information. Relevant materials also are available from the Commission’s website at http://www.ftc.gov.

It helps the Commission’s analysis to hear from a variety of sources in its work on antitrust and consumer protection issues, and we appreciate your interest in this matter.

By direction of the Commission, Commissioner Harbour and Commissioner Kovacic recused.

Donald S. Clark  
Secretary